Predictive value of bcl-2 immunoreactivity in prostate cancer patients treated with radiotherapy

被引:21
|
作者
Bylund, A
Stattin, P
Widmark, A
Bergh, A [1 ]
机构
[1] Umea Univ, Dept Pathol, S-90185 Umea, Sweden
[2] Umea Univ, Dept Urol, S-90185 Umea, Sweden
[3] Umea Univ, Dept Oncol, S-90185 Umea, Sweden
关键词
prostate cancer; transurethral resection; bcl-2; immunohistochemistry; prognostic marker; radiation; survival;
D O I
10.1016/S0167-8140(98)00111-X
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and purpose: Recent experimental evidence suggests that overexpression of bcl-2, a protein functioning by blocking apoptosis, may influence the treatment outcome in human tumours, including prostate cancer. To test the clinical implications of this hypothesis, rumours from patients with prostate cancer treated with external beam radiotherapy were investigated for bcl-2 immunoreactivity (IR) and correlated with prognosis and treatment outcome. Materials and methods: Bcl-2 IR was evaluated in archival tumour specimens obtained through transurethral resection from 42 patients with localized prostate cancer (T0-T4, NO and MO). Bcl-2 IR expression was related to stage, grade and cancer-specific survival. Specimens were obtained prior to administrating routine radiotherapy for all patients. Results: Bcl-2 IR was present in 19/42 (45%) tumours. The bcl-2-positive patients had a significantly longer cancer-specific survival than the bcl-2-negative patients (10.3 Versus 3.4 years, P < 0.04). At follow-up (7-19 years), nine patients were still alive, 26 patients had died of prostate cancer and seven patients had died of other causes. Conclusions: This study indicates that pre-treatment bcl-2 overexpression is related to a favourable outcome in prostate cancer treated with radiotherapy. Low bcl-2 along with a high stage may be a predictor of poor prognosis and these patients might benefit from additional treatment. (C) 1998 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:143 / 148
页数:6
相关论文
共 50 条
  • [1] bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer
    Mackey, TJ
    Borkowski, A
    Amin, P
    Jacobs, SC
    Kyprianou, N
    [J]. UROLOGY, 1998, 52 (06) : 1085 - 1090
  • [2] The prognostic value of pretreatment expression of androgen receptor and bcl-2 in hormonally treated prostate cancer patients
    Noordzij, MA
    Bogdanowicz, JFAT
    vanKrimpen, C
    vanderKwast, TH
    vanSteenbrugge, GJ
    [J]. JOURNAL OF UROLOGY, 1997, 158 (05): : 1880 - 1884
  • [3] The prognostic value of pretreatment expression of androgen receptor and bcl-2 in hormonally treated prostate cancer patients - Comment
    Reiter, RE
    [J]. JOURNAL OF UROLOGY, 1997, 158 (05): : 1884 - 1885
  • [4] BCL-2 in prostate cancer: A minireview
    S. D. Catz
    J. L. Johnson
    [J]. Apoptosis, 2003, 8 : 29 - 37
  • [5] BCL-2 in prostate cancer: A minireview
    Catz, SD
    Johnson, JL
    [J]. APOPTOSIS, 2003, 8 (01) : 29 - 37
  • [6] Prognostic value of Bcl-2 in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy
    Vargas-Roig, Laura M.
    Cuello-Carrion, F. Dario
    Fernandez-Escobar, Nicolas
    Daguerre, Pedro
    Leuzzi, Marcela
    Ibarra, Jorge
    Gago, Francisco E.
    Nadin, Silvina B.
    Ciocca, Daniel R.
    [J]. MOLECULAR ONCOLOGY, 2008, 2 (01) : 102 - 111
  • [7] BCL-2 IMMUNOREACTIVITY IN NEUROBLASTOMAS
    FURMAN, J
    SWANSON, PE
    COFFIN, CM
    DEHNER, LP
    [J]. LABORATORY INVESTIGATION, 1994, 70 (01) : A146 - A146
  • [8] Predictive value of immunohistochemistry with p21, bcl-2 and p53 to pre-operative radiotherapy for patients with rectal cancer
    Zlobec, I
    Vuong, T
    Compton, CC
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (01): : S295 - S295
  • [9] Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy
    Yoshino, Tateki
    Shiina, Hiroaki
    Urakami, Shinji
    Kikuno, Nobuyuki
    Yoneda, Tatsuaki
    Shigeno, Kazushi
    Igawa, Mikio
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (20) : 6116 - 6124
  • [10] Could bcl-2, bax, and p53 immunohistochemical alternations become predictive markers for radiotherapy of localized prostate cancer?
    Kariya, S
    Ogawa, Y
    Nishioka, A
    Furihata, M
    Kasahara, K
    Yoshida, S
    [J]. RADIOLOGY, 2001, 221 : 225 - 225